Points to consider regarding the use and implementation of virtual controls in nonclinical general toxicology studies-Reference-Cited by-同舟云学术

Points to consider regarding the use and implementation of virtual controls in nonclinical general toxicology studies

Published:2024-06 Issue: Volume:150 Page:105632
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Palazzi Xavier^ORCID,Anger Lennart T.,Boulineau Theresa,Grevot Armelle,Guffroy Magali,Henson Kristin^ORCID,Hoepp Natalie,Jacobsen Matt^ORCID,Kale Vijay P.^ORCID,Kreeger John^ORCID,Lane Joan H.^ORCID,Li Dingzhou,Muster Wolfgang^ORCID,Paisley Brianna,Ramaiah Lila^ORCID,Robertson Nicola^ORCID,Shultz Valerie,Steger Hartmann Thomas^ORCID,Westhouse Richard

Publisher

Elsevier BV

Reference21 articles.

1. FDA and industry collaboration: identifying opportunities to further reduce reliance on nonhuman primates for nonclinical safety evaluations;Ackley;Regul. Toxicol. Pharmacol.,2023

2. Evaluation of clinical pathology data: correlating changes with other study data;Everds;Toxicol. Pathol.,2015

3. Toward implementing virtual control groups in nonclinical safety studies;Golden;ALTEX,2023

4. Toxicologic pathology Forum opinion fiece: use of virtual control groups in nonclinical toxicity studies: the anatomic pathology perspective;Grevot;Toxicol. Pathol.,2024

5. Hurdles and signposts on the road to virtual control groups-A case study illustrating the influence of anesthesia protocols on electrolyte levels in rats;Gurjanov;Front. Pharmacol.,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endeavours made by trade associations, pharmaceutical companies and regulators in the replacement, reduction and refinement of animal experimentation in safety testing of pharmaceuticals;Regulatory Toxicology and Pharmacology;2024-09

2. Historical control data of rare events: Issues, chronological patterns and their relevance for toxicological evaluations;Regulatory Toxicology and Pharmacology;2024-08

3. Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation;Clinical Pharmacology & Therapeutics;2024-07-17